Lantheus Announces New Patient Outcomes Data for DEFINITY to be Presented at the American Society of Echocardiography 2019 Annual Scientific Sessions
Lantheus Holdings, Inc. (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that new clinical outcomes data for DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension in intensive care unit patients will be presented at the American Society of Echocardiography (ASE 2019) Annual Scientific Sessions, being held June 21-25, 2019, at the Oregon Convention Center in Portland, Oregon. Lantheus will also host a scientific symposium and interactive panel discussion focused on enhanced echocardiography. DEFINITY is a cardiovascular ultrasound contrast agent currently indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.1
Details for the poster presentation are as follows:
Title: Impact of Contrast Echocardiography on Clinical Outcomes in Critically Ill Patients
Date and Time: Monday, June 24, 2019, 9:00 a.m.-4:00 p.m. PT
Author Discussion: Michael Main, M.D., Cardiologist, Saint Luke’s Mid America Heart Institute at 11:45 a.m.-1:15 p.m. PT
Location: Exhibit Hall C
Poster number: P2-114
Details for the scientific symposium and interactive panel discussion are as follows:
Title: Enhanced Echocardiography: It’s What You Don’t See That Matters
Date and Time: Saturday, June 22, 2019, at 11:30 a.m.-1:00 p.m. PT
Speakers: Ben Lin, M.D., Ph.D., Director, Interventional Echocardiography, Yale New Haven Hospital; Theresa Green, RDCS, Echocardiography Advanced Coordinator, Piedmont Hospital; and Sean McMahon,
M.D., FACC, Associate Director, Echocardiography Laboratory, Hartford Hospital
Location: Science and Technology Theater, Exhibit Hall B
SDMS credit is available
Lesen Sie auch
About DEFINITY
DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal
echocardiograms (see Indications and Important Safety Information below and find full Prescribing Information at www.definityimaging.com).1 DEFINITY is engineered to produce small and consistently sized durable microbubbles to fully evaluate the left
ventricle.1 DEFINITY has extensive safety experience and a consistent safety profile.2 Since its launch in 2001, more than 11 million echo studies have been performed with
DEFINITY and it is the most prescribed contrast agent in the U.S.3